Cotadutide
- Generic Name
- Cotadutide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C167H252N42O55
- CAS Number
- 1686108-82-6
- Unique Ingredient Identifier
- QL6A9B13HW
- Background
Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes).
- Associated Conditions
- -
- Associated Therapies
- -
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05668936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT05364931
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04208620
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath